Urine dipstick demonstrates higher sensitivity and specificity than laboratory urinalysis for diagnosing urinary tract ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

US and MCUG for all children aged <2 years. 99m Tc–DMSA scan in high-grade reflux [3] Urinary tract infection (UTI) is the most common serious bacterial infection in childhood, and its ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

The FDA has approved Blujepa (gepotidacin), a first-in-class oral antibiotic for uncomplicated urinary tract infections (uUTIs) in women and children aged 12 and older. Clinical trials showed its ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.

The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

The UTI Children's Equity Fund - Growth- Direct has an AUM of 1064.98 crores & has delivered CAGR of 18.33% in the last 5 years. The fund has an exit load of 0.00% and an expense ratio of 1.19%.

The UTI Children's Hybrid Fund - Scholarship Plan has an AUM of 4560.50 crores & has delivered CAGR of 9.79% in the last 5 years. The fund has an exit load of 0.00% and an expense ratio of 1.73%.